Our drug delivery technology based on lipidic nanoemulsions allows for safe and physiological intracellular delivery of complex macromolecules (peptides, proteins and nucleic acids) and small hydrophobic molecules. The platform has broad and fresh IP protection and is fully scalable and regulatory compliant.
At DIVERSA, we want to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients' quality of life.
Despite the discovery of many new targets and therapeutic molecules in labs around the world, less than 3% of them will make it to clinical stages. Most of these new molecules are discarded in the early stages of research, mostly because they cannot access the interior of the cell, where 3 out of 4 new molecules have their targets. We want change that. We want to spearhead the therapeutic revolution.
Company Details
- Employees
- 22
- Founded
- -
- Address
- Edificio Emprendia, Campus Sur, Santiago De Compostela,15782,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- nanotechnology, intracellular delivery, biotechnology, Drug delivery system, Small molecule delivery, Protein delivery, Peptide delivery, mRNA delivery, siRNA delivery, DNA delivery.
- HQ
- Santiago de Compostela
Diversa Technologies Questions
Diversa Technologies's website is https://www.diversatechnologies.com
Diversa Technologies's LinkedIn profile is https://es.linkedin.com/company/diversatechnologies
Diversa Technologies has
22 employees.
View email and phone details for 22
employees at Diversa Technologies.
Diversa Technologies's industry is
Biotechnology Research
Diversa Technologies's top competitors are
Biopolo Sionlla,
Galchimia,
Celtarys Research,
Flowreserve Labs,
Bflow,
Bioga,
Enzicas,
Sunrock Biopharma, S.l,
Hifas Da Terra S.l.,
Liberabio.
Diversa Technologies's categories are Biotechnology Research
Diversa Technologies's founding year is 2022
